Showing 3841-3850 of 8849 results for "".
- Study Links Vitiligo to Higher Autoimmune and Infection Burden in US Cohorthttps://practicaldermatology.com/news/vitiligo-linked-to-higher-autoimmune-and-infection-burden-in-us-cohort/2486572/New data from a large retrospective study suggested patients with vitiligo experience higher rates of several comorbidities and safety events compared with matched controls. Investigators analyzed Optum Market Clarity EHR dat
- ILDS, WHO Launch Global Dermatology Training Hub to Address Care Gapshttps://practicaldermatology.com/news/ilds-who-launch-global-dermatology-training-hub-to-address-care-gaps/2486380/The International League of Dermatological Societies (ILDS), in collaboration with the World Health Organization (WHO), has launched the ILDS Dermatology Training Hub, a free online platform aimed at expanding access to dermatology education worldwide. The initiati
- Lutikizumab Improves Clinical Response Rates in Moderate to Severe HS: Analysishttps://practicaldermatology.com/news/lutikizumab-shows-promise-in-hs-after-anti-tnf-failure-in-phase-2-trial/2486330/In a phase 2, double-blind, placebo-controlled randomized clinical trial, lutikizumab demonstrated efficacy signals in adults with moderate to severe hidradenitis suppurativa (HS) who had previously experienced anti–tumor necrosis factor (TNF) therapy failure.
- Study: Tumor Location and Histologic Features Linked to Melanoma Recurrencehttps://practicaldermatology.com/news/study-tumor-location-and-histologic-features-linked-to-melanoma-recurrence/2485922/In patients with stage I–II melanoma, tumor location and histopathologic features were linked with recurrence risk beyond traditional factors such as ulceration and tumor thickness, according to a new study. Investigators exa
- Analysis: Biologics Linked to Lower Cardiometabolic Risk in HShttps://practicaldermatology.com/news/analysis-biologics-linked-to-lower-cardiometabolic-risk-in-hs/2485805/Biologics were associated with a lower incidence of type 2 diabetes mellitus (T2DM) and cardiovascular events vs. no biologic use in a TriNetX cohort of 291,283 patients with hidradenitis suppurativa (HS), according to a new study in the Journal of Drugs in Dermatology. Investigat
- Nutrafol Launches Men 50+ Formula Targeting Age-Related Hair Thinninghttps://practicaldermatology.com/news/nutrafol-launches-men-50-formula-targeting-age-related-hair-thinning/2485568/Nutrafol announced an expansion of its men’s portfolio with the launch of Nutrafol Men 50+, a product designed specifically for men aged 50 years and older with thinning hair. According to the company, men entering their 50s ex
- Vitiligo Linked to Elevated Risk of Herpes Zoster: Cohort Studyhttps://practicaldermatology.com/news/vitiligo-linked-to-elevated-risk-of-herpes-zoster-study-finds/2485328/A new cohort study from Taiwan indicated vitiligo is independently associated with a heightened risk of herpes zoster (HZ), with systemic immunosuppressive therapies compounding the risk further. Using data from Taiwan's Longit
- Discrimination, Language Gaps Undermine HS Care for Latine Adults: Analysishttps://practicaldermatology.com/news/latine-patients-with-hs-face-barriers-in-pain-and-wound-care-study-finds-discrimination-language-gaps-undermine-hs-care-for-latine-adults/2485130/Latine patients with hidradenitis suppurativa (HS) continue to face barriers to care, according to a qualitative study published in JAMA Dermatology. Study researchers analyzed transcripts from semistructured interviews
- Lower Neighborhood SES Linked to Increased HS Severity at Diagnosis: Analysishttps://practicaldermatology.com/news/lower-neighborhood-ses-linked-to-increased-hidradenitis-suppurativa-severity-at-diagnosis/2483997/New research suggests that lower neighborhood socioeconomic status (nSES) was associated with more severe hidradenitis suppurativa (HS) at the time of diagnosis. The recent cross-sectional analysis of 462 patients newly diagno
- FDA Approves Libtayo for Adjuvant Treatment of High-Risk CSCChttps://practicaldermatology.com/news/fda-approves-libtayo-for-adjuvant-treatment-of-high-risk-cscc/2483899/The FDA has approved cemiplimab-rwlc (Libtayo, Regeneron) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence following surgery and radiation, according to a statement from the agency.